CN101883577A - 使用抗原性肽和化疗剂的胰腺癌组合疗法 - Google Patents

使用抗原性肽和化疗剂的胰腺癌组合疗法 Download PDF

Info

Publication number
CN101883577A
CN101883577A CN2008801133893A CN200880113389A CN101883577A CN 101883577 A CN101883577 A CN 101883577A CN 2008801133893 A CN2008801133893 A CN 2008801133893A CN 200880113389 A CN200880113389 A CN 200880113389A CN 101883577 A CN101883577 A CN 101883577A
Authority
CN
China
Prior art keywords
seq
peptide
cancer
aminoacid
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801133893A
Other languages
English (en)
Chinese (zh)
Inventor
山上裕机
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN101883577A publication Critical patent/CN101883577A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2008801133893A 2007-08-24 2008-08-19 使用抗原性肽和化疗剂的胰腺癌组合疗法 Pending CN101883577A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
US60/957,923 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (1)

Publication Number Publication Date
CN101883577A true CN101883577A (zh) 2010-11-10

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801133893A Pending CN101883577A (zh) 2007-08-24 2008-08-19 使用抗原性肽和化疗剂的胰腺癌组合疗法

Country Status (19)

Country Link
US (1) US8703713B2 (enExample)
EP (1) EP2195003A4 (enExample)
JP (1) JP5417667B2 (enExample)
KR (1) KR20100047899A (enExample)
CN (1) CN101883577A (enExample)
AR (1) AR068020A1 (enExample)
AU (1) AU2008292966C1 (enExample)
BR (1) BRPI0815726A2 (enExample)
CA (1) CA2697501A1 (enExample)
IL (1) IL204143A (enExample)
MX (1) MX2010002178A (enExample)
MY (1) MY160406A (enExample)
NZ (1) NZ583578A (enExample)
RU (1) RU2472522C2 (enExample)
SG (1) SG183770A1 (enExample)
TW (1) TWI436775B (enExample)
UA (1) UA100702C2 (enExample)
WO (1) WO2009028150A1 (enExample)
ZA (1) ZA201001580B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101139392B (zh) 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
US20130149302A1 (en) * 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
SG11201702391RA (en) * 2014-10-09 2017-04-27 Univ Yamaguchi Car expression vector and car-expressing t cells
KR20230004907A (ko) * 2014-10-14 2023-01-06 립타이드 바이오사이언스, 인코포레이티드 항-염증 특성을 갖는 펩타이드
JP7168228B2 (ja) * 2017-05-19 2022-11-09 慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) * 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
CA2158745C (en) * 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
WO1999059636A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN101139392B (zh) * 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CA2567836A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
BRPI0807654A2 (pt) 2007-02-16 2014-06-03 Oncotherapy Science Inc Terapia com vacinas para a neovascularização de coroide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Also Published As

Publication number Publication date
MY160406A (en) 2017-03-15
UA100702C2 (ru) 2013-01-25
NZ583578A (en) 2012-07-27
JP5417667B2 (ja) 2014-02-19
IL204143A (en) 2013-04-30
RU2472522C2 (ru) 2013-01-20
CA2697501A1 (en) 2009-03-05
EP2195003A4 (en) 2011-07-06
JP2010536714A (ja) 2010-12-02
US20110082088A1 (en) 2011-04-07
ZA201001580B (en) 2011-02-23
KR20100047899A (ko) 2010-05-10
AU2008292966A1 (en) 2009-03-05
MX2010002178A (es) 2010-03-18
AU2008292966B2 (en) 2012-07-19
AR068020A1 (es) 2009-10-28
BRPI0815726A2 (pt) 2016-01-05
WO2009028150A1 (en) 2009-03-05
EP2195003A1 (en) 2010-06-16
US8703713B2 (en) 2014-04-22
AU2008292966C1 (en) 2013-03-14
SG183770A1 (en) 2012-09-27
TWI436775B (zh) 2014-05-11
RU2010111139A (ru) 2011-09-27
TW200914037A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
CN101883577A (zh) 使用抗原性肽和化疗剂的胰腺癌组合疗法
Fujiwara et al. The role of tumor-specific Lyt-1+ 2-T cells in eradicating tumor cells in vivo. I. Lyt-1+ 2-T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
JP5555952B2 (ja) Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
Coluccia et al. Anti-leukaemic action of RuCl2 (DMSO) 4 isomers and prevention of brain involvement on P388 leukaemia and on P388DDP subline
EP2192179B9 (en) Cdh3 peptide and medicinal agent comprising the same
CN101568550A (zh) 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
MX2008010842A (es) Peptido de tumor de wilms restringido por antigeno leucocitario humano-a*3303 y composicion farmaceutica que comprenden el mismo.
CN109803674A (zh) Calr和jak2疫苗组合物
ES2382821T3 (es) Polipéptidos capaces de estimular una reacción inmune contra el cáncer
ES2340357T3 (es) Antigeno tumoral.
Dao et al. Peptide vaccines for myeloid leukaemias
JP5954174B2 (ja) 免疫誘導剤
El-Zawahry et al. Cost and outcome of treatment of adults with acute myeloid leukemia at the National Cancer Institute-Egypt
KR20220012261A (ko) 체외 성분채집술에 의한 체크포인트 억제제에 대한 반응 증가
KR102632061B1 (ko) Pd-l1에 대해 증가된 결합력을 갖는 당화 pd-1 변이체
CN112142824B (zh) 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
US20210198319A1 (en) Cytotoxic peptides and conjugates thereof
CN110305209B (zh) 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
Rüttinger et al. Current immunotherapeutic strategies in lung cancer
Adler et al. Active, specific immunotherapy of stage III breast cancer: Results of an exploratory study
CN116059387A (zh) 一种抗胰腺癌的疫苗、及其医药用途
US20220160812A1 (en) A pharmaceutically active substance
WO2024216241A2 (en) Heteroclitic neoepitope vaccines
JP2002356498A (ja) 滑膜肉腫抗原ペプチド
Wiseman et al. Whole-Cell Breast Cancer Vaccine/GMCSF: Clinical Experience in 13 Patients with Cell Line SV-BR1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20160113

C20 Patent right or utility model deemed to be abandoned or is abandoned